Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 1000-1005

  Zheng, Hong ^a   Gao, Yunong ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Benign pelvic disease; Endometriosis; HE4; Ovarian cancer; Pelvic inflammatory disease

Indexed keywords

CA 125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEIN; EPIDIDYMAL SECRETORY PROTEIN E4; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CYSTADENOMA; CYTOREDUCTIVE SURGERY; DISEASE MARKER; ENDOMETRIOSIS; FEMALE; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVARY ENDOMETRIOSIS; PELVIC INFLAMMATORY DISEASE; PREMENOPAUSE; PREOPERATIVE PERIOD; PRIORITY JOURNAL;

CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIOSIS; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; PROTEINS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863607263     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318249bee7     Document Type: Article

References (14)

1. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98:172-180.
2. Olaitan A, Weeks J, Mocroft A, et al. The surgical management of women with ovarian cancer in the south west of England. Br J Cancer. 2001;85:1824-1830.
3. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102:499-505.
4. Canis M, Rabischong B, Houlle C, et al. Laparoscopic management of adnexal masses: a gold standard? Curr Opin Obstet Gynecol. 2002;14:423-428.
5. Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76: 2092-2096.
6. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-408.
7. Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374-382.
8. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440-445.
9. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
10. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315-1319.
11. Porpora MG, Koninckx PR, Piazze J, et al. Correlation between endometriosis and pelvic pain. J Am Assoc Gynecol Laparosc. 1999;6:429-434.
12. Nagle CM, Olsen CM, Webb PM, et al. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer. 2008;44:2477-2484.
13. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-2169.
14. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28:2159-2166.